Why Is Viridian Therapeutics Stock Trading Higher On Tuesday? - Viridian Therapeutics ( NASDAQ:VRDN )

a week ago

Tuesday, Viridian Therapeutics, Inc. VRDN released topline data from the THRIVE phase 3 clinical trial of VRDN-001 ( veligrotug ) , an intravenously delivered anti-insulin-like growth factor-1 receptor ( IGF-1R ) antibody, for active thyroid eye disease ( TED ) .

Ticker	Sentiment	Impact
VRDN	Bullish	38 %